*This form should be completed by outline applicants for the Developmental Pathway Funding Scheme (DPFS), with reference to the Guidance for Outline Stage Applicants.*

*Use the Tab key to move between cells in the form. Cells that are greyed out* ***do not*** *need to be filled in, since these are automatically calculated from fields elsewhere in the form. To ensure that all the automatic calculations in Section 8 of the document pull correctly, please start from the first entry and use the “Tab” key to navigate between the ‘cost’ cells. Alternatively, press F9 to update all fields.*

*When completed, this form must be converted to a pdf file and submitted via the Joint electronic Submission (Je-S) system as part of an Outline Application**for DPFS funding as an attachment under document type “Case for Support”.*

*Version 8.2*

 *September 2022*

Section 1: Project Summary

|  |
| --- |
| **1.1 Title (max 150 characters) [same as Je-S Project Title]** |
|       |

|  |
| --- |
| **1.2 Technical Summary (max 2000 characters) [same as Je-S Technical Summary]** |
|       |

|  |
| --- |
| **1.3 Project Duration and Cost [same as in Je-S submission]** |
| **Proposed start date****(dd.mm.yyyy)** |       |
| **Proposed duration of award****(Months)** | 0 |
| **Project fEC****(£000s)** | 0 |
| **Estimated MRC Contribution @ 80% fEC (£000s)** | 0 |
| **Project Partner Contribution****(£000s)** | 0 |

Section 2: Investigator Details

Please also refer to [Section 1.3 of the MRC Guidance for Applicants](https://www.ukri.org/councils/mrc/guidance-for-applicants/check-if-you-are-eligible-for-funding/1-3-applicants/#contents-list) for definitions and further information on applicant roles.

|  |
| --- |
| **2.1 Principal Investigator [same as Je-S Principal Investigator]** |
| **Name** |       |
| **Post Held** |       |
| **Department** |       |
| **Institution** |       |

|  |
| --- |
| **2.2 Co-Investigators [same as Je-S Co-Investigators]** |
| **Name** | **Institute / Organisation / Company** |
|       |       |
|       |       |
|       |       |
|        |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |

|  |
| --- |
| **2.3 Researcher Co-Investigators [same as Je-S Researcher Co-Investigators]** |
| **Name** | **Institute / Organisation / Company** |
|       |       |
|       |       |
|       |       |

|  |
| --- |
| **2.4 Industrial Project Partners [Project Partners in Je-S]** |
| **Name** | **Institute / Organisation / Company** |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |

|  |
| --- |
| **2.5 Non-Industrial Project Partners (Collaborators) [Project Partners in Je-S]** |
| **Name** | **Institute / Organisation / Company** |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |

|  |
| --- |
| **2.6 Subcontractors** |
| **Name** | **Institute / Organisation / Company** |
|       |       |
|       |       |
|       |       |
|       |       |
|       |       |

Section 3: Host Institute Technology Transfer Office Contact

|  |
| --- |
| **3.1 Host Institute Technology Transfer Office (TTO) Contact** |
| **Name** |       |
| **Post Held** |       |
| **Department** |       |

Section 4: Need

|  |
| --- |
| **4.1** **What is the health, clinical or product development need you are seeking to address? (max 120 words)** |
|       |

|  |
| --- |
| **4.2 What is your proposed solution to meeting this need? (max 120 words)** |
|       |

|  |
| --- |
| **4.3 Please list and describe the competing solutions (in academia and industry), and their developmental status? (max 500 words)** |
|       |

|  |
| --- |
| **4.4 What is the competitive advantage of your proposed solution? (max 300 words)** |
|       |

|  |
| --- |
| **4.5 What is the market for the proposed solution? Please quantify this in terms of the target product profile, patient numbers and financial parameters (max 250 words)** |
|       |

Section 5: Rationale

|  |
| --- |
| **5.1 What is the rationale and supporting evidence for why your proposed solution will meet the targeted need? (max 500 words)** |
|       |

|  |
| --- |
| **5.2 Please provide up to 10 relevant references (max 250 words)** |
|       |

Section 6: Deliverability

|  |
| --- |
| **6.1 What is the current status of the project? (max 100 words)** |
|       |

|  |
| --- |
| **6.2 Please list the project’s primary objectives (max 150 words)** |
|       |

|  |
| --- |
| **6.3 Please list the project’s specific intended deliverables (max 100 words)** |
|       |

|  |
| --- |
| **6.4 In the case of applications involving Institutes, Units or Centres with existing core funding, including those funded by MRC and NIHR (i.e. BRCs & BRUs), please describe how the proposed research and associated request for funds builds on, but is distinct from, core funded programmes of research (max 150 words)** |
|       |

|  |
| --- |
| **6.5** **Please give details of previous / concurrent awards relevant to the project, stating the funder, time awarded, grant period, grant title and £s awarded, alongside a short summary of how each supported the current application. If you currently hold any funding concurrent to this project, please give details of any overlap and how this work will support your application (max 500 words)** |
|       |

|  |
| --- |
| **6.6 How will the project achieve its objectives? Summarise the project workplan, including at least two key progression milestones (one being the project end). For each Milestone, please set out the success criteria that will be used, and detail robust Go / No-Go criteria (max 1250 words)** |
|       |

|  |
| --- |
| **6.7 Where applicable, please justify the use of animals or patients. Why have these particular animal models or clinical populations been chosen? (max 250 words)** |
|       |

|  |
| --- |
| **6.8 For clinical studies, please outline the recruitment and retention strategy (max 200 words)** |
|       |

|  |
| --- |
| **6.9 Have you consulted with a statistician, CTU or methodology hub during the development of the application, and will you have access to statistical support during the project? If not, please summarise why this is not necessary (max 300 words)** |
|       |

|  |
| --- |
| **6.10 Please summarise the statistical analysis plan and the proposed sample sizes, providing sufficient detail for replication of any power calculations and a clear summary of the anticipated effect sizes and variability.** **Consider potential sources of biases and describe strategies that will be adopted to minimise their effects (1 page)** |
|       |

|  |
| --- |
| **6.11** **Identify and justify the skills and resources (materials, methods, data, people, infrastructure, outsourced tasks, etc.) needed to undertake the proposed project. Please specify the need, the costs and the timelines of usage / employment with respect to achievement of each stated milestone (max 500 words)** |
|       |

|  |
| --- |
| **6.12 How will the project be managed, and what experience does the team have of managing similar projects? (max 200 words)** |
|       |

|  |
| --- |
| **6.13 Please list the key risks to delivering the project, how likely these are to occur, and what their impact would be on the success and deliverability of the project? How will these risks be managed? What mitigation plans will be in place? (max 500 words)** |
|       |

Section 7: Downstream Project Support and Intellectual Property

Note that the generation of protectable intellectual property is **not** an essential requirement for this scheme; projects that will not generate patentable materials but that will nevertheless have the potential to provide health benefits are accepted on an equal basis. However, ownership and management of IP **must** be consistent with MRC’s funding requirements. Projects with no plausible route to exploitation and ultimate health benefit or impact are extremely unlikely to be supportable.

|  |
| --- |
| **7.1** **What new IP or knowledge is the project expected to generate? (max 200 words)** |
|       |

|  |
| --- |
| **7.2 How will project-generated IP be managed and exploited to support the project in meeting its targeted need? Detail the organisations / individuals who will own any arising IP and any live, pending or envisioned agreements governing ownership or exploitation of that IP (max 200 words)** |
|       |

|  |
| --- |
| **7.3 Following the end of the grant award, how will the project be supported to enable it to meet its ultimate objectives (i.e., what is the route to market / patient benefit)? (max 200 words)** |
|       |

|  |
| --- |
| **7.4 What sources of subsequent funding / partners are available to the project? What criteria will need to be met in order to access these funds / partnerships, and how will the planned programme of work help to meet these criteria? (max 200 words)** |
|       |

|  |
| --- |
| **7.5 If you are ultimately seeking to develop a commercial product, please outline the potential market value and how this will be realised (e.g., business development plans) (max 200 words)** |
|       |

|  |
| --- |
| **7.6 Do the applicants have freedom to operate for this project, for future development work, and / or for clinical use? If access is required, what IP does the proposal need access to? (max 200 words)** |
|       |

|  |
| --- |
| **7.7 If access to background IP is required, please detail the institutions or individuals that hold the relevant background IP rights. If this background IP is held by a third party (or a non-academic applicant), has access been agreed? If not, why do you believe you will be able to access the required IP on reasonable terms? (max 200 words)** |
|       |

Section 8: Project Duration and Cost

*To ensure that all the automatic calculations pull correctly, please start from the first entry and use the “Tab” key to navigate between the ‘cost’ cells in Section 8 of the document. Alternatively, press F9 to update all fields.*

|  |  |  |
| --- | --- | --- |
| **Step** | **Duration****(months)** | **fEC Cost****(£000s)** |
| **Milestone 1** | 0 | 0 |
| **Milestone 2** | 0 | 0 |
| **Milestone 3 [if applicable]** | 0 | 0 |
| **Milestone 4 [if applicable]** | 0 | 0 |
| **Entire Project fEC** | 0 | 0 |
| **Estimated MRC Contribution @ 80% fEC (same as Je-S total)** |  | 0 |
| **Project Partner Contribution** |  | 0 |

|  |
| --- |
| **8.1 If you have requested support for resources under Exceptions Costs, please describe the nature of these resources (max 200 words)** |
|       |

|  |
| --- |
| **8.2 Please summarise any NHS costs (excess treatment and NHS support costs) that the project will require (max 200 words)** |
|       |